HG146

DRUG3 trials

Sponsors

HitGen Inc.

Conditions

Adenoid Cystic CarcinomaHead and Neck CancerLymphomaMultiple MyelomaRelapsed and Refractory Multiple MyelomaSolid Tumor

Phase 1

A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma

TerminatedNCT03710915

HitGen Inc.Multiple Myeloma, Relapsed and Refractory Multiple Myeloma

Start: 2019-01-12End: 2023-06-28Updated: 2024-10-10

Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma

RecruitingNCT04977167

HitGen Inc.Lymphoma, Solid Tumor

Start: 2023-07-28End: 2024-12-31Target: 96Updated: 2024-10-10

Phase 2

Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma

RecruitingNCT06781567

HitGen Inc.Adenoid Cystic Carcinoma, Head and Neck Cancer

Start: 2024-12-13End: 2029-06-30Target: 140Updated: 2025-03-14

Related Papers

Abstract CT139: A phase I study of HG146: A novel selective HDAC inhibitor, as single-agent in patients with advanced solid tumors and lymphomas

Cancer Research2025-04-25